Get the Stockscreener App
0.764
8.29%
-0.0691
After Hours:
.77
0.006
+0.79%
Ironwood Pharmaceuticals Inc stock is traded at $0.764, with a volume of 1.11M.
It is down -8.29% in the last 24 hours and up +6.53% over the past month.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
See More
Previous Close:
$0.8331
Open:
$0.8057
24h Volume:
1.11M
Relative Volume:
0.49
Market Cap:
$123.63M
Revenue:
$400.57M
Net Income/Loss:
$9.21M
P/E Ratio:
19.10
EPS:
0.04
Net Cash Flow:
$146.36M
1W Performance:
-6.78%
1M Performance:
+6.53%
6M Performance:
-67.35%
1Y Performance:
-88.81%
1-Day Range:
$0.7582
$0.8497
1-Week Range:
$0.7582
$0.9481
52-Week Range:
$0.5271
$6.935
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Name
Ironwood Pharmaceuticals Inc
Sector
Phone
617-621-7722
Address
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
0.764 | 134.81M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
145.79 | 66.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 42.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.43 | 43.30B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.45 | 19.30B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
128.23 | 13.53B | 2.41B | 305.80M | 492.20M | 2.95 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-08-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jan-17-24 | Initiated | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Wells Fargo | Overweight |
| Nov-09-23 | Initiated | Jefferies | Buy |
| Sep-28-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-02-22 | Initiated | CapitalOne | Overweight |
| Apr-22-22 | Initiated | Piper Sandler | Overweight |
| Sep-30-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-20 | Initiated | Northland Capital | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Mar-27-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-19 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Jan-24-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-07-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-07-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-23-18 | Initiated | H.C. Wainwright | Sell |
| May-09-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-06-17 | Downgrade | Mizuho | Buy → Neutral |
| Jul-21-17 | Downgrade | JP Morgan | Overweight → Neutral |
| May-03-17 | Initiated | Wells Fargo | Outperform |
| Apr-07-17 | Reiterated | Mizuho | Buy |
| Feb-22-17 | Reiterated | Barclays | Equal Weight |
| Nov-04-16 | Reiterated | Mizuho | Buy |
| Oct-24-16 | Reiterated | Wedbush | Neutral |
| Oct-10-16 | Reiterated | Mizuho | Buy |
| Sep-27-16 | Reiterated | WallachBeth | Hold |
View All
Ironwood Pharmaceuticals Inc Stock (IRWD) Latest News
How hedge fund analytics apply to Ironwood Pharmaceuticals Inc. stockAI Driven Buy Alert Trade Blueprint Released - metal.it
What makes Ironwood Pharmaceuticals Inc. stock price move sharplyCommunity Entry Consensus Trade Ideas Shared - metal.it
Ironwood Pharmaceuticals Inc. Recovery Likely Here’s What Data ShowsReal Time Alerts Based on AI Prediction Triggered - metal.it
Heatmap Data Shows High Activity in Ironwood Pharmaceuticals Inc. SectorAccurate Buy Point for Momentum Stocks Detected - metal.it
What are the latest earnings results for Ironwood Pharmaceuticals Inc.Achieve superior capital gains with smart trades - jammulinksnews.com
Is it the right time to buy Ironwood Pharmaceuticals Inc. stockOutstanding trading profits - jammulinksnews.com
What are Ironwood Pharmaceuticals Inc. company’s key revenue driversFree Stock Market Real-Time Monitoring - jammulinksnews.com
What catalysts could drive Ironwood Pharmaceuticals Inc. stock higher in 2025Maximize your investment portfolio’s performance - jammulinksnews.com
How strong is Ironwood Pharmaceuticals Inc. company’s balance sheetGet timely market insights for better trades - jammulinksnews.com
Is Ironwood Pharmaceuticals Inc. stock overvalued or undervaluedRecord-setting profit potential - jammulinksnews.com
Ironwood Pharmaceuticals Inc. Stock Analysis and ForecastAccelerated capital growth - PrintWeekIndia
Ironwood Pharmaceuticals Inc: Analyzing IRWD Stock Trends - investchronicle.com
What drives Ironwood Pharmaceuticals Inc. stock priceTriple-digit wealth increases - Autocar Professional
What analysts say about Ironwood Pharmaceuticals Inc. stockHigh-yield market plays - Autocar Professional
Is Ironwood Pharmaceuticals Inc. a good long term investmentRapid portfolio appreciation - jammulinksnews.com
How the Irritable Bowel Syndrome (IBS) Treatment Market Will - openPR.com
How Ironwood Pharmaceuticals Inc. stock performs during market volatilityTop Gaining Low Risk Assets - Newser
Why Ironwood Pharmaceuticals Inc. stock attracts strong analyst attentionHigh Confidence Trade Setups - Newser
Endometriosis Pain Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine - The Globe and Mail
Endometriosis Pain Pipeline 2025: FDA Updates, Therapy Innovations, And Clinical Trial Landscape Analysis By Delveinsight Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, Abbvie/Neurocrine - MenaFN
Ironwood Pharmaceuticals Inc Stock (IRWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):